Previous close | 42.79 |
Open | 43.97 |
Bid | 43.23 x 100 |
Ask | 43.50 x 100 |
Day's range | 43.17 - 44.46 |
52-week range | 14.42 - 60.90 |
Volume | |
Avg. volume | 875,265 |
Market cap | 2.539B |
Beta (5Y monthly) | 1.76 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SOUTH SAN FRANCISCO, Calif., September 12, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the U.S. Green Building Council (USGBC) awarded the company’s Wilsonville, OR facility LEED certification, meeting sustainability standards for its building, operations and maintenance.
SOUTH SAN FRANCISCO, Calif., September 09, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its 2024 corporate responsibility report detailing Twist’s approach to sustainability, social responsibility and ethics. The report highlights Twist’s ongoing commitment to advancing sustainable initiatives to best serve customers, communities and the planet.
SOUTH SAN FRANCISCO, Calif., August 27, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird Global Healthcare Conference 2024 in New York City on Tuesday, September 10 at 2:35 p.m. Eastern Time.